Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Grows By 51.6%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 112,200 shares, a growth of 51.6% from the February 29th total of 74,000 shares. Based on an average daily trading volume, of 555,200 shares, the days-to-cover ratio is presently 0.2 days.

Astellas Pharma Trading Down 1.7 %

Shares of ALPMY opened at $10.75 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31. Astellas Pharma has a 12-month low of $10.29 and a 12-month high of $16.91. The firm has a 50-day moving average price of $11.07 and a 200 day moving average price of $12.09. The firm has a market capitalization of $19.45 billion, a P/E ratio of 28.05, a P/E/G ratio of 2.66 and a beta of 0.32.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Monday, February 5th. The company reported $0.12 earnings per share for the quarter. The company had revenue of $2.86 billion during the quarter. Astellas Pharma had a net margin of 0.08% and a return on equity of 6.39%. Sell-side analysts forecast that Astellas Pharma will post 0.28 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.